Peter Ho, M.D. ’90, Ph.D. ’90, joins Epizyme Inc.

Peter Ho, M.D. ’90, Ph.D. ’90, has been named chief development officer at Epizyme Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers. Ho will lead Epizyme’s clinical development, regulatory, and translational medicine functions. His prior experience includes positions at Johnson & Johnson, GlaxoSmithKline, DuPont Pharma, and Novartis.